About tecovirimat monohydrate
Antiviral; orthopoxvirus inhibitor
Used for
- Treats smallpox in adults and children weighing at least 3 kg.
- Treats mpox and other orthopoxvirus infections when approved or authorized.
Usual adult dose
200 mg by mouth every 12 hours for 14 days, taken with a full meal.
Usual dose in children
Children weighing at least 3 kg receive weight-based doses every 12 hours for 14 days; capsules are for children weighing at least 13 kg who can swallow them.
Common side effects
- Headache
- Nausea
- Abdominal pain
- Vomiting
Important warnings
- Human effectiveness evidence is limited; treatment is authorized for specific situations.
- Take each oral dose with a full meal for adequate absorption.
- May reduce effectiveness of some medicines, including midazolam and repaglinide.
- Use caution with severe kidney impairment when given with intravenous tecovirimat.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether tecovirimat enters human milk; data on effects are limited.
Interactions
- Tecovirimat can reduce midazolam and repaglinide exposure.
- Other medicines that depend on CYP3A or CYP2C8 may have reduced effectiveness.
- Strong CYP3A inducers, such as rifampin, may reduce tecovirimat levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.